Search results
Results from the WOW.Com Content Network
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...
[65] [64] Statin-induced rhabdomyolysis is rare, occurring in less than 0.1% of people who take statins. [66] [67] [68] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [66]
Part of the power of statins lies in the fact that they cause few side effects. “Generally, about 90 out of 100 people have no trouble with a stain,” says Dr. Blumenthal. These Are the Statin ...
Instead, the guidelines recommended that cost-effectiveness analyses focus on "costs per relevant clinical outcome." [ 27 ] [ 30 ] In response to the ECHOUTCOME study, representatives of the National Institute for Health and Care Excellence, the Scottish Medicines Consortium , and the Organisation for Economic Co-operation and Development made ...
These guidelines recommend statin therapy for adults between forty and seventy-five who have diabetes, high cholesterol levels, or an estimated 10-year atherosclerotic cardiovascular disease risk ...
[citation needed] Annual cost to the UK National Health Service (NHS) in 2018, for 5–40 mg rosuvastatin daily (of one person) was £24-40, compared to £10-20 for 20–80 mg simvastatin. [ 38 ] In 2013, it was the fourth-highest-selling drug in the United States, accounting for approximately $5.2 billion in sales. [ 39 ]
The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus, and increased liver enzymes in the blood due to liver damage. [5] [66] Over 5 years of treatment statins result in 75 cases of diabetes, 7.5 cases of bleeding stroke, and 5 cases of muscle damage per 10,000 people treated. [35]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]